BACKGROUND: Medication side effects and limited efficacy are substantial problems in general and also in psychopharmaceuticals. Previous studies have shown that pharmacogenetic individual characteristics can be relevant.
AIM: To arrive at a responsible use of pharmacogenetics, exploiting its potential but also avoiding overdiagnosis.
METHOD: To provide an overview of the current status quo in the field of pharmacogenetics in psychiatry.
RESULTS: The Dutch Association for Psychiatrists (NVvP) authorized a guideline ‘Pharmacogenetics in Psychiatry’ that is summarized. Also the current international guidelines and clinical implementation of pharmacogenetics are discussed.
CONCLUSION: For the time being, pharmacogenetics seems to be indicated only when patients have already experienced problems with psychopharmaca use, such as side effects and/or inefficacy. If genotyping is requested then generally CYP2C19 and CYP2D6 can be useful, as dosage recommendations are available in case of genetic variants.
|Translated title of the contribution||Current status quo on Pharmacogenetics in psychiatry|
|Number of pages||5|
|Journal||Tijdschrift voor Psychiatrie|
|Publication status||Published - 2022|
- Cytochrome P-450 CYP2D6/genetics
- Psychotropic Drugs